CardiAQ Valve Technologies v. Neovasc 

June 10, 2016

BOSTON, MA – After a 3-week trial in the U.S. District Court of Massachusetts, a jury panel decided in favor of CardiAQ Valve Technologies, Inc., a subsidiary of Edwards Life Sciences.  CardiAQ was awarded $70 million as a result of Neovasc, Inc.’s misappropriation of its transcatheter mitral valve trade secrets.

Edwards was represented by a team from Knobbe, Martens, Olsen & Bear, LLP.  Impact Trial’s team members were Alison Von Dollen, Leah Tran, Justin Chauncey, and Randall Carter, led by Thomas S.Y. Lee.  The Impact team provided medical illustrations, demonstrative design and in-court presentations for the duration of the case.

Impact has cultivated a long-standing relationship with Edwards by providing specialized support for various medical device related cases in the past. We are incredibly proud of having had the opportunity to serve Edwards once again. Impact is equally pleased with the outcome of this patent infringement case against Neovasc, Inc.

The case is CardiAQ Valve Technologies, Inc. v. Neovasc, Inc. et al., case number 1:14-cv-12405, in the U.S. District Court for the District of Massachusetts.